Eocene Ltd
galmedpharma.comWhat Do They Do?
Develops Aramchol for combination treatment of gastrointestinal cancers and pursues other biotech and medical-technology candidates for gastrointestinal and cardiometabolic conditions.
20-F for FY2025, filed Mar 31, 2026We are currently seeking to advance the development of Aramchol for combination therapy for GI oncological indications. In addition, as…View ↗
How Are They Changing?
New oncology focus
The older report centered on Aramchol for liver disease and anti-fibrotic indications; the latest report says the company is advancing it for combination treatment of gastrointestinal cancers and pursuing other gastrointestinal and cardiometabolic candidates.
20-F for FY2022, filed Mar 29, 2023 20-F for FY2025, filed Mar 31, 2026We are a biopharmaceutical company focused on the development of Aramchol. Historically, we have focused almost exclusively on developing…View ↗
In May 2022, we announced our plan to expand into new anti-fibrotic indications to maximize the potential of Aramchol while at the same…View ↗
We are currently exploring the feasibility of developing Aramchol for other indications outside of liver disease and anti-fibrotic…View ↗
Who Do They Compete With?
Competes with Novo Nordisk, Madrigal Pharmaceuticals, and Viking Therapeutics
20-F for FY2025, filed Mar 31, 2026Our competitors in the NASH field currently include companies with marketed products and/or advanced clinical programs. Our main…View ↗
Loading...
